Switch theme
Sign up to access all valuation multiples
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
2018
274
LTM Revenue $38.0M
LTM EBITDA -$243M
-$30.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Verve Therapeutics has a last 12-month revenue (LTM) of $38.0M and a last 12-month EBITDA of -$243M.
In the most recent fiscal year, Verve Therapeutics achieved revenue of $32.3M and an EBITDA of -$222M.
Verve Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Verve Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $38.0M | XXX | $32.3M | XXX | XXX | XXX |
| Gross Profit | $38.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$243M | XXX | -$222M | XXX | XXX | XXX |
| EBITDA Margin | -638% | XXX | -686% | XXX | XXX | XXX |
| EBIT | -$235M | XXX | -$229M | XXX | XXX | XXX |
| EBIT Margin | -617% | XXX | -707% | XXX | XXX | XXX |
| Net Profit | -$210M | XXX | -$199M | XXX | XXX | XXX |
| Net Margin | -552% | XXX | -615% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Verve Therapeutics's stock price is $4.
Verve Therapeutics has current market cap of $398M, and EV of -$30.9M.
See Verve Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$30.9M | $398M | XXX | XXX | XXX | XXX | $-2.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Verve Therapeutics has market cap of $398M and EV of -$30.9M.
Verve Therapeutics's trades at -1.0x EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Verve Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Verve Therapeutics has a P/E ratio of -1.9x.
See valuation multiples for Verve Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $398M | XXX | $398M | XXX | XXX | XXX |
| EV (current) | -$30.9M | XXX | -$30.9M | XXX | XXX | XXX |
| EV/Revenue | -0.8x | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -0.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -2.0x | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVerve Therapeutics's last 12 month revenue growth is -4%
Verve Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Verve Therapeutics's rule of 40 is -1855% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Verve Therapeutics's rule of X is -648% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Verve Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -638% | XXX | -686% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | -1855% | XXX | -690% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -648% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 632% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 807% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Verve Therapeutics acquired XXX companies to date.
Last acquisition by Verve Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Verve Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Verve Therapeutics founded? | Verve Therapeutics was founded in 2018. |
| Where is Verve Therapeutics headquartered? | Verve Therapeutics is headquartered in United States of America. |
| How many employees does Verve Therapeutics have? | As of today, Verve Therapeutics has 274 employees. |
| Who is the CEO of Verve Therapeutics? | Verve Therapeutics's CEO is Dr. Sekar Kathiresan, M.D.. |
| Is Verve Therapeutics publicy listed? | Yes, Verve Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Verve Therapeutics? | Verve Therapeutics trades under VERV ticker. |
| When did Verve Therapeutics go public? | Verve Therapeutics went public in 2021. |
| Who are competitors of Verve Therapeutics? | Similar companies to Verve Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Verve Therapeutics? | Verve Therapeutics's current market cap is $398M |
| What is the current revenue of Verve Therapeutics? | Verve Therapeutics's last 12 months revenue is $38.0M. |
| What is the current revenue growth of Verve Therapeutics? | Verve Therapeutics revenue growth (NTM/LTM) is -4%. |
| What is the current EV/Revenue multiple of Verve Therapeutics? | Current revenue multiple of Verve Therapeutics is -0.8x. |
| Is Verve Therapeutics profitable? | Yes, Verve Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Verve Therapeutics? | Verve Therapeutics's last 12 months EBITDA is -$243M. |
| What is Verve Therapeutics's EBITDA margin? | Verve Therapeutics's last 12 months EBITDA margin is -638%. |
| What is the current EV/EBITDA multiple of Verve Therapeutics? | Current EBITDA multiple of Verve Therapeutics is 0.1x. |
| What is the current FCF of Verve Therapeutics? | Verve Therapeutics's last 12 months FCF is -$222M. |
| What is Verve Therapeutics's FCF margin? | Verve Therapeutics's last 12 months FCF margin is -583%. |
| What is the current EV/FCF multiple of Verve Therapeutics? | Current FCF multiple of Verve Therapeutics is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
